Scientists gain insights into traffic cop function of gene expression protein

December 18, 2018

CHAPEL HILL, NC - Scientists at the UNC School of Medicine have discovered a crucial quality-control mechanism inside cells that, when it fails, might contribute to major diseases including cancers.

The discovery, published in Cell Reports, concerns the process of gene transcription or gene expression - the copying of a gene's DNA into RNA - the essential first step in turning genetic information into functional molecules such as proteins. The UNC-Chapel Hill scientists found that an enzyme called casein kinase II adds small chemical modifications or "molecular tags" onto Spt6, a key protein in the transcription process that enables Spt6 to wind back up the DNA after transcription. This rewinding prevents inappropriate transcription from occurring in the wrong direction along the gene. Such a "wrong way" situation can lead to serious health conditions.

"We made this finding in yeast cells, but all the players are found in human cells, too, and many of them are linked to human disease," said senior author Brian Strahl, PhD, professor, vice chair, and Oliver Smithies Investigator in the department of biochemistry and biophysics and member of the UNC Lineberger Comprehensive Cancer Center.

How gene transcription works so efficiently and accurately most of the time is one of the great mysteries of biology, in large part because of DNA's almost unbelievably tight packaging. The DNA in a single human cell would be about six feet long if unraveled, but somehow it manages to fit within the cell nucleus.

"One of the big questions in our field," Strahl said, "is how cells manage to wind up so much DNA but keep it carefully organized and indexed so DNA can be accessed at the right place and time?"

Scientists know part of the answer already. The DNA in our cells is wound onto millions of spool-like structures made of proteins called histones. Each histone spool and its wrapped DNA is referred to as a nucleosome. When a cell needs to transcribe a stretch of DNA, the histones and their helper proteins called "histone chaperones" loosen up the nucleosome so that the molecular machinery of transcription can access the hidden DNA. When the process of transcription is complete, the histone chaperones then usually put nucleosomes back together and keep DNA firmly wrapped. How this crucial and complex job is performed so well across the genome is not fully known.

In their new study, Strahl and his team found an important piece of this puzzle: a new function of an enzyme that makes a histone chaperone function properly, which in turn helps prevent the serious errors in DNA-wrapping that lead to disrupted gene transcription. Both the enzyme casein kinase II and the histone chaperone Spt6 were already known to be involved in gene transcription, though their precise roles were unclear.

The UNC scientists found that casein kinase II activates Spt6 in a way that allows the chaperone protein to work with histones to properly batten down DNA. The enzyme performs this activation by chemically attaching phosphorylation groups (i.e., molecular tags) onto Spt6. "Phosphorylation" is a common method by which cells switch a protein's function from "on" to "off" or the other way around.

To study the importance of the phosphorylation on Spt6, the UNC scientists reengineered Spt6 slightly so that it could no longer be modified by the kinase, and found that Spt6 wasn't performing its job well in putting nucleosomes back together. Curiously, this effect was more pronounced on the nucleosomes at the starting point of gene transcription, which led to a peculiar form of abnormal transcription.

"We observed an increase in transcripts that run from the start of the gene backwards through the gene's regulatory or so called "promoter" region - where transcription begins - not downstream as normal," said study first author Raghuvar Dronamraju, PhD, a research assistant professor in the Strahl laboratory.

The scientists concluded that casein kinase II's crucial phosphorylation of Spt6 allows it to place histones back at the beginning of genes in order to help it enforce normal gene transcription in the right direction.

"It's like a traffic cop at an intersection, allowing cars to travel in one direction but not another," Strahl said.

This basic science discovery could lead to medically important insights because loss of the ability to control transcription can be harmful to cells, for example by allowing stretches of DNA that don't code for genes to be expressed. This can interfere with normal transcription. It can also lead to neighboring genes being improperly activated if nucleosomes are not re-inserted at their promoters to block new transcription after a gene is supposed to be shut down.

Such transcriptional mis-regulation can result in serious diseases such as cancer (for example, if a tumor suppressor gene is affected). In fact, any derangement of the normal dynamics of DNA packaging is potentially a cause of major illness. Strahl said many of the proteins involved in packaging and unpackaging our DNA have been found at abnormal levels or are mutated in many cancers, and some of these proteins are being eyed as potential cancer drug targets.

In follow-up experiments, Strahl, Dronamraju, and colleagues hope to determine how exactly Spt6 exerts its DNA-organizing effect particularly at the upstream ends of genes and how it interacts with other histone chaperone proteins.
The National Institutes of Health (GM126900, CA166447, CA198482), the Corn-Hammond Fund for Pediatric Oncology, and the National Science Foundation (MCB 1515748) funded this research.

University of North Carolina Health Care

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to